Author Archives: syoligo

In October 2025, Sylentis participated in the annual conference of the Oligonucleotide Therapeutics Society (OTS) held in Budapest, one of the most important international meetings in the field of RNA-based

Interview with Ana Isabel Jiménez, Managing Director of Sylentis, on the occasion of OTS Budapest 2025 From 19 to 22 October 2025, Sylentis will participate in the Oligonucleotide Therapeutics Society

The manufacture of therapeutic oligonucleotides is advancing, driven by the ability of these molecules to treat diseases that until now lacked effective options. However, synthesising oligonucleotides is only part of

The latest edition of Farmaforum 2025, held in Madrid, once again brought together the main players in the pharmaceutical and biotechnology industry. Among the protagonists was Sylentis, which actively participated

The advancement of oligonucleotide-based therapies has marked a turning point in modern medicine. In this context of accelerated innovation, contract development and manufacturing organisations, known as CDMOs, have taken on

The beneficiary companies participate in the Major Project of Common European Interest in Health (IPCEI) Med4Cure, which aims to bring innovations against diseases for which there are no effective means

Oligonucleotide-based treatments capable of silencing specific genes have made it possible to tackle previously untreatable diseases ranging from muscular dystrophies (eteplirsen (2016), golodirsen (2019), vitolarsen (2020), casimersen (2021)) to certain

For decades, the search for and optimisation of new therapeutic agents has been an arduous, costly and largely stochastic process. In recent years, however, artificial intelligence (AI) has burst into

Antisense oligonucleotides (ASOs) are small synthetic nucleic acid sequences that have the potential to transform the treatment of genetic and multifactorial eye diseases previously considered untreatable. What are ASOs and